Author: BioCeuticals - Editor
The first patient to complete our ground-breaking medicinal cannabis clinical trial says the treatment has given her hope for the future.
Suffering from a Stage 4 recurring brain tumour, Elizabeth Coady from Hobart, Tasmania, completed the phase 2, randomised, double-blind clinical trial on 1 March 2019 after receiving a daily dose of oral liquid supplement over a 12-week period.
“Participating in the trial has given me more hope in prolonging my life,” said Elizabeth.
“And even though the medicinal cannabis may not help me in the long run, I’m proud that the trial will go on to help people in the future.”
Initially diagnosed with glioblastoma multiforme (GBM) in May 2018, Elizabeth, with the support of husband Dean, applied to participate in the medicinal cannabis trial after seeing an interview with lead researcher at Endeavour College of Natural Health Dr Janet Schloss on Channel Nine’s Today show.
“I thought I would jump in and try and see if we would get in. I didn’t think our chances were good, but we were lucky enough to meet the criteria” said Elizabeth.
The trial, funded by BioCeuticals, is being led by Dr Schloss in conjunction with internationally renowned neurosurgeon, Professor Charlie Teo. It will determine whether orally ingested organic medicinal cannabis is well-tolerated by patients suffering from GBM – a highly aggressive form of primary brain tumour. It will also investigate whether medicinal cannabis can affect tumour growth and improve quality of life, when used alongside patients’ standard cancer treatments.
The trial came just in time for Elizabeth, who was diagnosed with three additional tumours in November 2018. As a symptom of her GBM, she began high dose medication to control her frequent seizures. Since beginning the trial, there has been no further tumour growth and Elizabeth has been seizure free as of 28 December 2018.
Elizabeth is now continuing medicinal cannabis treatment alongside her standard therapy and believes the trial will create an important standard body of evidence, which would encourage greater uptake of the complementary therapy worldwide.
“It’s really important. If it has the ability to stop or reduce my seizures, then there are some real benefits to be had from this treatment. It is another medicine and should be treated that way – we feel strongly about that,” said Elizabeth.